

JAN 1 5 2003 Attorney's Docket No. 702-002214

		AMENDMEN	TRANSMI	TTAL LETTE	R	8	EC.		
HAN	D DELIVERED					<u></u>	n		
USPTO Technology Center 1600, Reception Area, 7 th Floor							구		
Sequence Information							G		
Crystal Mall One, 1911 South Clark Street							- =		
Arlington, VA 22202						===	38		
•	•					ः ऽ	2		
Serial No.: <u>09/720,278</u> Filing Date: <u>May 24, 2001</u>							/290		
Examiner: Not Yet Assigned Group Art Unit: 1614									
Invention: "Pharmaceutical Preparations For Use in Combatting or Preventing Surface Infections									
Caused by Microorganisms"									
Transı	mitted herewith is an A	mendment in	the above-ident	ified applicatio	n.				
				• •					
	Small entity status of this application under 37 CFR 1.27 has been established by								
	verified statement previously submitted. A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed. No additional fee is required.								
	The fee has been calculated as shown below:								
	No. of Claims	Highest No.		Small	Non-Small				
	After	Previously	Present	Entity	Entity				
	Amendment	Paid For	Extra	Rate	Rate	Ch	arge		
Total _	16	20	0X	\$ 9.00	X \$ 18.00	\$			
Indep.	3	3	-0- X	\$ 42.00	X \$ 84.00	\$			
First P	resentation of Multiple	Dep. Claim		+ \$140.00	+ \$280.00	\$			
	Total Additional Fee					\$			
			Total	raditional 1 cc		Φ	<u>0-</u>		
	A check in the	A check in the amount of \$ is enclosed to cover the filing fee.							
	A check in the amount of \$ is enclosed to cover the fining fee. A check in the amount of \$ is enclosed for amonth Petition for Extension of						of Time		
	The Commissioner is hereby authorized to charge payment of the following fee associated with this communication to Deposit Account No. 23-0650. Please refund an overpayment to Deposit Account No. 23-0650. An original and two copies of this shee are enclosed. X Any additional filing fees required under 37 CFR 1.16. X Any patent application processing fees under 37 CFR 1.17.								
	rmy patent up	prication proce	ssing ices unde	1 37 CFR 1.17.					
				// -	• /				
January 8, 2003 By Justice of John									
							_		
		Barbara E Johnson Registration No. 31,198							
	Attorney for Applicants 700 Koppers Building 436 Seventh Avenue								
			Pittsbu	ırgh, PA 15219	-1818				

Telephone: (412) 471-8815 Facsimile: (412) 471-4094

E-mail: webblaw@webblaw.com



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO.

09/720,278 Pieter Jacob Swart 702-002214

INTERNATIONAL APPLICATION NO.

PCT/EP99/04067

Russell D Orkin 700 Koppers Building 436 Seventh Avenue Pittsburgh, PA 15219-1818 I.A. FILING DATE PRIORITY DATE 06/28/1999 06/26/1998

CONFIRMATION NO. 9397
371 FORMALITIES LETTER
OC000000009279679

Date Mailed: 12/23/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Claims
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- · Copy of the International Search Report
- Drawings
- Information Disclosure Statements
- Initial Application Filing Fees
- Oath or Declaration
- · Oath or Declaration
- Original Specification
- Preliminary Amendments

Applicant's response filed 05/24/2001 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 03/30/2001 have not been completed.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
 - See attached explanation.
 - APPLICANT MUST PROVIDE:
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.					
09/720,278	PCT/EP99/04067	702-002214					

FORM PCT/DO/EO/916 (371 Formalities Notice)

#12

PATENT APPLICATION Serial No. 09/720,278 Atty. Docket No. 702-002214

PHARMACEUTICAL PREPARATION FOR USE IN COMBATTING OR

PREVENTING SURFACE INFECTIONS CAUSED BY MICROORGANISMS

Confirmation No. 9397

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit 1614

In re application of :

Pieter Jacob SWART et al.

Serial No. 09/720,278 :

Filed May 24, 2001

Examiner Not Yet Assigned

Pittsburgh, Pennsylvania

January 8, 2003

SEQUENCE AMENDMENT

HAND DELIVERED

United States Patent and Trademark Office Technology Center 1600, Reception Area, 7th Floor Sequence Information Crystal Mall One, 1911 South Clark Street Arlington, VA 22202

Sir:

In response to the "Notification of Defective Response" mailed December 23, 2002 pursuant to the "Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" mailed March 30, 2001, pursuant to 37 C.F.R. § 1.821 *et seq.*, Applicants submit the following Sequence Listing and corresponding computer readable form (CRF) for insertion into the specification. Applicants also submit the following amendments and remarks.

IN THE SPECIFICATION

Please delete the current version of the Sequence Listing and replace it with the attached Sequence Listing for the above-identified patent application.

{W0037043.1}